A 3-MONTH RANDOMIZED CONTROLLED TRIAL OF BIMATOPROST (LUMIGAN) VERSUS TIMOLOL/DORZOLAMIDE (COS - OPT) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION A. Coleman, P. Bern-
摘要: <正> Objective: To compare efficacy and safety of bimato-prost (Lumigan) QD vs timolol/dorzolamide (Cosopt) BID. Methods: Randomized, double-masked, multicenter 3-month clinical trial. 177 patients with glaucoma or ocular hypertension with uncontrolled intraocular pressure (IOPs between 22 and 34 mmHg) after at least 2 weeks of timolol 0.5% monotherapy were ...
(共2頁)
開通會(huì)員,享受整站包年服務(wù)